Synthetic Biologics Reports Expected Q1 Results and Kohl's Corporation Reports Disappointing Earnings

Synthetic Biologics Inc. (NYSE: SYN) reported its first-quarter results revealing a loss of $3.84 million, or 7 cents a share. This was in line with the Capital IQ Consensus Estimate of a loss of 7 cents a share. The company did not report any revenue but plans to start a 28-day bridging toxicology study in June for its SYN-004 oral enzyme for the prevention of C. difficile infections. Synthetic Biologics also expects to start Phase Ia and Ib clinical trials in the second half of 2014, with preliminary topline data expected by the end of the year. The company further plans to begin a Phase